An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.5c24385 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Juan Tao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced Drug Formulations f…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Ionic Liquids, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Huai'an Science and Technology Bureau, Lingang Laboratory.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Oral delivery of peptide therapeutics remains challenging due to gastrointestinal degradation, poor epithelial permeability, and extremely low bioavailability. To address these limitations, we developed an enteric solid formulation based on sorbic acid-choline ionic liquids (ILs) for the oral delivery of semaglutide (Sema), a glucagon-like peptide-1 (GLP-1) analogue. The IL-based enteric system was designed to enhance peptide stability, reduce gastric degradation, and promote intestinal absorption. In vitro studies demonstrated strong resistance to acidic conditions and pH-responsive release in simulated intestinal fluid. In vivo imaging further revealed prolonged intestinal retention of the IL-loaded enteric particles. Pharmacokinetic evaluation showed a 2.3-fold increase in maximum plasma concentration compared to the reference Rybelsus. In type 2 diabetes mellitus (T2DM) mice, the formulation achieved glucose-lowering efficacy comparable to subcutaneous Sema administration, with additional improvements in hepatic histology. Importantly, repeated-dose studies indicated favorable systemic and gastrointestinal tolerability under the tested conditions. Collectively, these results demonstrate that IL-based enteric formulation enhances oral peptide exposure while maintaining safety, offering a promising strategy for noninvasive T2DM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai 201203, Ch…
- School of Chinese Medicine, Jiangsu College of Nursing, Huaian 223001, China.
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China.
ORCID-Profile: Jinlong Yang, Jianping Qi
Förderung
- Huai'an Science and Technology Bureau
- Lingang Laboratory
Zitieren
APA
Tao, J., Lu, X., Wei, Y., Feng, J., Yang, J., & Qi, J. (2026). An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c24385
Vancouver
Tao J, Lu X, Wei Y, Feng J, Yang J, Qi J. An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c24385
BibTeX
@article{Tao2026,
author = {Tao, Juan and Lu, Xinrui and Wei, Yuning and Feng, Jiayi and Yang, Jinlong and Qi, Jianping},
title = {An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.5c24385}
}
EUVIMED